Signal active
Bio
Richard Aldrich is a co-founder of Concert Pharmaceuticals and has served as our Chairman of the Board since May 2006.
Richard Aldrich co-founded Longwood Founders Fund in 2010, a fund that starts and invests in biotechnology companies, and currently serves as a Partner in the firm.
Prior to Longwood, he was General Partner of RA Capital, a biotech investment fund he founded in 2001.
Richard Aldrich was a co-founding employee of Vertex Pharmaceuticals where he held the position of Senior Vice President and Chief Business Officer and managed all commercial and operating functions from 1989 to 2001.
Prior to joining Vertex, Richard Aldrich held several management positions at Biogen Inc. In addition to Concert, Richard Aldrich has co-founded and helped build several successful biotech companies including Sirtris Pharmaceuticals and Alnara Pharmaceuticals.
Richard Aldrich received his undergraduate degree from Boston College, and an MBA from the Amos Tuck School at Dartmouth College.
Location
N/A
Social
Primary Organization
2010
60
11
16
11-50
Venture Capital, Finance
Jobs history
2
Axial Biotherapeutics
Board Member
Invalid date - Current
Director
2017 - 2022
Board and Advisor Roles
0
N/A
Invest in regions
Profile Resume
Richard Aldrich is the Co - Founder & Partner at Longwood Fund. With a background in Venture Capital, Richard Aldrich has a rich history of leadership and innovation. Richard Aldrich studied MBA unknown @ Tuck School of Business at Dartmouth College. Explore their detailed professional journey, key connections, and contributions to the industry on our platform.
Investment portfolio
2
0
Personal investment
2
Annouced Date | Organization Name | Funding Round | Money Raised |
---|---|---|---|
Jan 01, 2024 | Altera | Pre Seed Round - Altera | 2.0M |
May 08, 2024 | Altera | Seed Round - Altera | 9.0M |
Partner investment
2
Annouced Date | Organization Name | Funding Round | Investor Name | Money Raised |
---|---|---|---|---|
Sep 10, 2014 | Colorescience | Series B - Colorescience | Longwood Fund | 15.0M |
Oct 13, 2021 | Axial Biotherapeutics | Series C - Axial Biotherapeutics | Longwood Fund | 37.3M |
Exits
0
There is no exit available on this Profile
Invest in industries
Recent Activity
There is no recent news or activity for this profile.